Drugs / GM-XANTHO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04369846 | May 2020 → Jan 2025 | atopic eczema | Xantho Biotechnology Co., LTD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06620692 | Oct 2025 → Dec 2027 expected | psoriasis | Xantho Biotechnology Co., LTD | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05199077 Comparator | Sep 2026 → Dec 2028 expected | decubitus ulcer, diabetes mellitus | Xantho Biotechnology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM-XANTHO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199077 ↗ |
| Known as | GM-XAN003 | “5% GM-XANTHO [GM-XAN003]” NCT06620692 ↗ |
| Route | Topical | “topically applied 2.5%, 5% GM-XANTHO” NCT05199077 ↗ |